Developing and applying potentially scalable recruitment strategies to accelerate ADRD research participation of Black adults
Authors:
Open Access
- 6 December 2024
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (2)
Abstract
More than 2 million older Americans from underrepresented racial and ethnic minority groups (URGs) have early‐stage Alzheimer's disease and related dementias (ADRD). There are very few scalable recruitment strategies, particularly for Black older adults, to accelerate participation in ADRD research. The Indiana Alzheimer's Disease Research Center (IADRC) and its Community Advisory Board developed and implemented the innovative RAAISE‐D Framework. This Framework informed the creation of community‐first recruitment strategies designed to accelerate participation of Black older adults in ADRD research. Preliminary outcomes from its implementation included the doubling of Black adult enrollment (46, 13.4% to 101, 26.9%) from April 2020 to April 2024. Black adults were more likely to have normal cognition, be female, and ≤ 12 years of education than non‐Hispanic White adults. The RAAISE‐D Framework identified key concepts for URG focused recruitment strategies which successfully accelerated enrollment of Black adults in ADRD research and could be generalized to other URGs. Highlights: RAAISE‐D Framework provides adaptable URG recruitment strategies. IADRC CAB‐researcher partnership was the foundation of community‐first methodology. RAAISE‐D Framework doubled the Black enrollment in the IADRC in 4 years.Keywords
Funding Information
- National Institute on Aging (5P30AG072976)
This publication has 41 references indexed in Scilit:
- Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed?JAMA, 2023
- Riding the merry‐go‐round of racial disparities in ADRD researchAlzheimer's & Dementia, 2023
- Barriers and facilitators to participating in Alzheimer's disease biomarker research in black and white older adultsAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2023
- Lecanemab Gains FDA Approval for Early Alzheimer DiseaseJAMA, 2023
- Factors influencing the participation of Black and White Americans in Alzheimer's disease biomarker researchAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2022
- Estimating prevalence of early Alzheimer's disease in the United States, accounting for racial and ethnic diversityAlzheimer's & Dementia, 2022
- Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4Alzheimer's & Dementia, 2022
- Recommendations to address key recruitment challenges of Alzheimer's disease clinical trialsAlzheimer's & Dementia, 2022
- Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease TrialJAMA Network Open, 2021
- Inclusion of Underrepresented Groups in Preclinical Alzheimer Disease Trials—Opportunities AboundJAMA Network Open, 2021